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Abstract
Background: There is a widely held expectation that screening for disease has adverse emotional impacts. The
aim of the current review is to estimate the short (< 4 weeks) and longer term (> 4 weeks) emotional impact of
such screening.
Methods: Studies selected for inclusion were (a) randomised controlled trials in which (b) participants in one arm
underwent screening and received test results, and those in a control arm did not, and (c) emotional outcomes
were assessed in both arms. MEDLINE via PubMed (1950 to present), EMBASE (1980 to present), PsycINFO (1985 to
present) using OVID SP, and CINAHL (1982 to present) via EBSCO were searched, using strategies developed with
keywords and medical subject headings. Data were extracted on emotional outcomes, type of screening test and
test results.
Results: Of the 12 studies that met the inclusion criteria, six involved screening for cancer, two for diabetes, and
one each for abdominal aortic aneurysms, peptic ulcer, coronary heart disease and osteoporosis. Five studies
reported data on anxiety, four on depression, two on general distress and eight on quality of life assessed between
one week and 13 years after screening (median = 1.3 years).
Meta-analyses revealed no significant impact of screening on longer term anxiety (pooled SMD 0.01, 95% CI -0.10,
0.11), depression (pooled SMD -0.04, 95% CI -.12, 0.20), or quality of life subscales (mental and self-assessed health
pooled SMDs, respectively: 0.03; -0.01, (95% CI -.02, 0.04; 0.00, 95% CI -.04, 0.03).
Conclusion: Screening does not appear to have adverse emotional impacts in the longer term (> 4 weeks). Too
few studies assessed outcomes before four weeks to comment on the shorter term emotional impact of screening.
Background
Screening for disease and estimating disease risk using
biomarkers such as cholesterol or blood pressure have
formed a routine part of healthcare for over 50 years
[1]. The term mass screening is often used when screen-
ing involves the examination of large populations or
cohorts. The emotional impact of such screening was
largely unquestioned until the publication of a paper
presenting evidence of increased absenteeism following
the detection of hypertension [2]. Since then there have
been numerous reports of the emotional impact of
screening upon anxiety, depression, intrusive and
troubling thoughts, and, amongst children, absence from
school and behavioural disturbance [3,4].
Screening is a complex event involving those targeted
in a range of possible outcomes: awareness of screening;
receipt of an invitation; undergoing a screening test;
receiving a test result and concern regarding the test
result (anxiety over a possible diagnosis as well as
potential concern over false positive or false negative
results). Awareness of screening appears not to induce
emotional distress [5]. Receipt of an invitation for
screening may, however, precipitate emotional distress
[6] although this is not always the case [7]. More uncer-
tainty and concern exist about the emotional impact of
the latter two stages. Individuals can react with concern,
anxiety and even depression when informed that they
have an elevated risk of developing a disease [8]. While
some emotional distress may be helpful, too much can
be debilitating [9]. Not only can distress reduce
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any medium, provided the original work is properly cited.individuals’ quality of life, it can also interfere with
information processing [10] and hence the ability to be
reassured or to make informed choices regarding future
treatment options. Emotional distress can also result in
people avoiding future surveillance [11-13].
Existing reviews of the emotional impact of screening
report few adverse effects on generalised and specific
anxiety, depression or quality of life [3,14-17]. Whilst
some studies report an increase in immediate emotional
distress, few report distress that is sustained in the
longer term. Furthermore, between-group analyses
reveal few enduring effects of being identified as having
an elevated risk of disease. For example, a meta- analysis
assessing standardised differences between those receiv-
ing positive compared with negative test results revealed
increased anxiety and depression within the first four
weeks of receiving test results but no difference after
four weeks [3]. These findings stand in contrast to a
widespread belief amongst healthcare providers that
screening for risk of disease has adverse emotional con-
sequences [18,19].
The evidence from these reviews is, however, limited
in two ways. First, only a minority included randomised
controlled trials (RCTs) [3,15] and none restricted inclu-
sion to RCTs, thereby limiting the ability to infer a cau-
sal connection between screening and emotional
outcomes. Second, the dominant comparisons reported
are non-randomised comparisons within screened
groups, i.e. between those receiving test results indicat-
ing an elevated risk of disease (screen positive) and
those receiving test results indicating no elevated risk
(screen negative). While such comparisons are impor-
tant for being able to assess and, where necessary,
attempt to prevent excess distress, they do not address
the question of interest from a population health per-
spective, namely, whether screening causes distress in
populations invited and participating in screening pro-
grammes. Estimating this with precision requires com-
parisons between those randomised to undergo
screening and those randomised not to undergo screen-
ing. We report here the first such meta-analytic compar-
ison using data from randomised controlled trials.
The primary aim of this review is to estimate the
immediate and longer term emotional impact of under-
going screening or risk assessment for disease. To
improve upon existing reviews, we include only rando-
mised controlled trials in which a principal analysis
reports emotional outcomes of the randomised groups,
i.e. trials where it is possible to compare emotional out-
comes in those randomised to undergo screening or risk
assessment with those randomised not to undergo such
testing. The secondary aim is to estimate the emotional
impact of receiving an elevated risk (screen positive) test
result, by comparing outcomes of this subgroup with
those receiving a non-elevated or average risk test result.
Methods
Data sources and searches
An electronic literature search was conducted using
MEDLINE via PubMed (1950 to present), EMBASE
(1980 to present), PsycINFO (1985 to present) using
OVID SP, and CINAHL (1982 to present) via EBSCO.
Initial searches used MEDLINE Major Topic terms
[Majr] Genetic Screening, Mass Screening, Risk Assess-
ment and screen* which were combined with disease
specific terms cancer, diabetes, heart, cardiovasc*, AIDS,
HIV, osteoporosis, Huntington*, emotional terms, includ-
ing emotion*, anxiety, distress*, depression, “quality of
life”,m o o d ,a n g e rand “distress thermometer” including
two measures of emotional distress (GHQ and K10) and
publication type “R a n d o m i s e dC o n t r o l l e dT r i a l ”.T h e
core search was further limited by excluding the terms
fetal distress, postpartum depression, prenatal, newborn,
and maternal, as well as decision aid* and intervention*
in the title. Search strategies were tailored to individual
databases (available on request).
The search yielded 1743 abstracts which were inde-
pendently reviewed by two authors, with disagreements
resolved by consensus. Thirty-nine papers appearing to
meet inclusion criteria based on abstract alone were
subject to full-text evaluation, resulting in 15 meeting
the eligibility criteria (Figure 1).
Six of the 15 eligible papers contained insufficient data
to be included in the meta-analyses and requests for
data were made of the authors. Data were provided for
three of the six papers; the remaining three were
excluded [20-22]. Cross-sectional and cited reference
searches were conducted on all papers meeting the
inclusion criteria.
Study selection
Studies considered eligible for the review were rando-
mised controlled trials (RCTs) in which adults in one
arm underwent screening or risk assessment and
another did not, and in which one measure of emotion
was reported on all participants. Emotion was defined
broadly to include measures of general mood states as
well as emotional well-being.
Data extraction and quality assessment
Data were extracted (REC) and independently checked
(TMM), with disagreements resolved by consensus.
Variables of interest included study participants, study
design (including number of arms), screening (disease
type), emotional outcome (type, time points) and test
results (positive or negative).
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Page 2 of 10Risk of bias was assessed by two authors in line with
recommended principles [23]. Specific domains exam-
ined were: allocation concealment i.e. adequate if allo-
cation is concealed from both participants and
researchers at least until the point of allocation to
groups; randomisation i.e.e v i d e n c eo ft r u e
randomisation, alternative forms of randomisation,
including quasi randomisations, were considered ineli-
gible; baseline comparability i.e. comparability of
groups at baseline, or alternatively, statistical adjust-
ment for baseline differences; validation of measures i.
e. evidence of reliability and validity of primary
1743 publications 
identified from four 
electronic databases and 
hand searches through 
relevant reviews, 
commentaries and studies. 
38 considered potentially 
eligible for inclusion 
1705 excluded.  
Reasons for exclusions include 
removal of duplicates or 
ineligible samples, designs or 
outcome measures. 
1 study identified from a hand 
search of reference sections, 
forward citation searches and 
contact with relevant authors 
15 eligible papers 
identified describing data 
from 14 trials. 
24 studies excluded.  
Reasons for exclusions: 
Ineligible study design n = 14 
Ineligible outcomes n = 6 
Ineligible sample n = 1 
Ineligible intervention n = 3 
Figure 1 Flow diagram outlining the search and inclusion stages of the systematic review.
Collins et al. BMC Public Health 2011, 11:603
http://www.biomedcentral.com/1471-2458/11/603
Page 3 of 10endpoint measures; and follow up i.e.o u t c o m e s
reported on a minimum of 80 percent of participants.
Data synthesis and analyses
The principal analysis involved comparing randomised
groups on emotional outcomes. The secondary analysis
involved comparing non-randomised subgroups of those
who had undergone screening and received either a
positive (elevated risk) or a negative (non elevated risk)
test result.
Data were pooled for comparable emotional outcomes
with effect sizes presented as standardised mean differ-
ence (SMD). The I
2 statistic was used to assess the
extent of heterogeneity present. Funnel plots were con-
sidered, but not reported, due to insufficient meta-ana-
lysed study data for meaningful interpretation.
Outcomes were categorised as short term (assessed
within one month of receipt of test results) and longer
term (assessed one month or longer after receipt of test
results). Where multiple assessments are reported, the
data presented from any one study are those taken as
t h et i m ep o i n tc l o s e s tt oa n df u r t h e s tf r o mr e c e i p to f
test results.
Sensitivity analyses were conducted to examine the
effects of screening approach and disease type. Sensitiv-
ity analysis was also conducted to explore the potential
impact of attenders versus non-attenders on the primary
outcome measures.
Raw data from screened and not-screened groups
were combined using a statistical method for one paper
[22] to create one overall ‘screened’ group to facilitate
primary analyses.
Results
Characteristics of included studies
Of the included 12 papers (Table 1), reporting data from
12 studies, nine involved screening for disease [24-32]
and three involved assessing risk of disease [33-35]. For
ease of reading, we describe all 12 studies as assessing
outcomes of screening. Ten [24-31,33,34] involved ran-
domisation into two groups (screened and not
screened), one [35] into three groups (screening plus/
minus optional health discussion and not screened) and
one [32] into four groups (screened, not screened, risk
education and screening plus risk education).
Four of the 12 studies assessed the impact of screen-
ing for cancer [27,29,31,32] with a further two studies
assessing the impact of screening for risk of developing
lung cancer, based on results of a genetic test [33,34].
Two studies assessed the impact of screening for type II
diabetes [25,30]. One study each assessed the impact of
screening for abdominal aortic aneurysms [24], osteo-
porosis [26], peptic ulcer [28], and coronary heart dis-
ease [35]. The primary emotional outcomes were
depression [24,25,33,34], anxiety [24-26,30,33], and qual-
ity of life [24-26,28-32] and general distress [35]. A
behavioural index of emotional distress (suicide) was
reported in one paper [27].
Anxiety was assessed using the state scale of the state-
trait anxiety inventory (STAI) [36] and the anxiety sub-
scale of the Hospital Anxiety and Depression Scale
(HADS) [37]. Measures assessing depression included
the depression sub-scale from the HADS and the Centre
for Epidemiological Studies Depression Scale (CES-D)
[38]. Quality of life was measured using the Nottingham
Health Profile (NHP) [39] and the Short Form Health
Survey (SF-12 and SF-36) [40]. General distress was
measured using the General Health Questionnaire
(GHQ-12) [41].
The 12 studies involved 170,045 participants. The
mean ages of participants across the studies ranged
from 41 to 69 years. The gender mix of participants ran-
ged from 35% to100% female.
Quality assessment of included studies
None of the studies included in the review was judged to
have a low risk of bias (table available on request). Three
of the 12 studies met four of the five criteria [24,28,33]
and were judged to have the lowest risk of bias. Five stu-
dies met three criteria [24,26,27,30,35], three met two cri-
teria [25,31,34], and one met only one criterion [29].
Validation of measures was the most commonly met cri-
terion and was met by all studies, followed by baseline
comparability which was met by 10 of the 12 studies.
Allocation concealment of participants to trial arm prior
to randomisation was the most common risk of bias,
with only three studies meeting this criterion.
Of the 12 included studies, nine involved screening for
disease [24-32] and three involved assessing risk of dis-
ease [33-35]. For ease of reading, we describe all 12 stu-
dies as assessing outcomes of screening (Table 2).
Data were pooled for studies reporting the same emo-
tional outcome. Pooling was conducted separately for
emotional outcomes assessed in the short term (less
than one month after screening) and those assessed in
the longer term (beyond one month). The primary com-
parison was between randomised groups, namely those
undergoing screening and those not undergoing screen-
ing. Secondary analysis involved non- randomised com-
parisons between those who had undergone screening
and received a positive test result (i.e. one indicating an
elevated risk of disease) and those who had undergone
screening and received a negative test result (i.e.o n e
indicating no elevated risk of disease).
Anxiety
Only one study assessed the impact of screening on
anxiety within four weeks of screening (n = 61) [33].
The pooled SMD was -0.50 (95% CI -1.06, 0.06)
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Five studies [24-26,30,33] assessed longer term anxiety
(n = 5,910). The pooled SMD was 0.01 (95% CI -0.10,
0.11), indicating no adverse effect of screening upon
anxiety beyond four weeks of screening.
Two studies [25,33] provided sufficient data to enable
quantitative synthesis of short term anxiety by screening
test outcome (n = 2,511). The pooled SMD was 0.06
(95% CI -0.02, 0.14) indicating no evidence of short
term anxiety in those receiving positive test results com-
pared with those receiving negative test results.
Two studies [24,33] provided sufficient data to enable
quantitative synthesis of longer term anxiety by screen-
ing test outcome (n = 1,273). The pooled estimate of
the overall standardised difference was -0.05 (95% CI
-0.53, 0.44) indicating no evidence of longer term anxi-
ety for those receiving positive test results compared
with those receiving negative results.
Table 1 Characteristics of included studies
Disease and Disease
risk
Assessment method First
Author
Reference
Number
Measures
(scale)
Groups (n) Follow-
up
Country
Screening for presence of Disease
Abdominal
Aortic
Aneurysms
(AAA)
Abdominal
Ultrasound
Ashton[24] State anxiety
(STAI
a),
Depression
(HADS
b),
QoL (SF-36)
Not-screened (726),
Screened (1230), Screen
+ve (599), Screen -ve
(631)
6
weeks
UK
Type II diabetes Random glucose blood test Eborall[25] State anxiety
(STAI
a),
Depression
(HADS
b), QoL (SF-
36)
Not-screened (444),
Screened (2874), Screen
+ve (880), Screen -ve
(1687)
12-15
months
UK
Park[30] State anxiety
(STAI
a), QoL (SF-
36)
Not-screened (168),
Screened (64)
6
weeks
UK
Osteoporosis Bone mineral density measurement Torgerson
[26]
State anxiety
(STAI
a), QoL (SF-
36)
Not-screened (605),
Invited (611)
2 years UK
Colorectal
Cancer
Faecal occult
blood test
Parker[27] General Distress -
Suicide
Not-screened (74,998),
Invited(75,253)
14
years
UK
Whynes[29] QoL (NHP
d) Not-Screened (396),
Screened (821)
5
months
UK
Ovarian Cancer CA-125 blood test, transvaginal sonography Andersen
[32]
QoL (SF-36) Not-Screened (139),
Screened (128)
2 years USA
Disease and Disease
risk
Assessment method First Author
Reference
Number
Measures
(scale)
Groups (n) Follow-
up
Country
Screening for presence of Disease cont.
Prostate, Lung,
Colorectal and
Ovarian Cancer
Screening
Digital rectal exam & PSA test (men), CA-
125 blood test & transvaginal ultrasound
(women), chest x- ray, flexible
sigmoidoscopy.
Taylor [31] QoL (SF-12) Not-screened (217),
Screened (215), Screen
+ve (105), Screen -ve
(61)
12
months
USA
Peptic Ulcer Helicobacter
pylori blood test.
Hansen [28] QoL (SF-36) Not-screened (5,612),
Screened (4,821)
5 years Denmark
Risk Assessment
Lung Cancer Genotyping
(GSTM1 gene)
Sanderson
[33]
Depression, State
Anxiety (HADS
b)
Not-screened (18),
Screened (43), Screen
+ve (23),
Screen -ve (20)
1 week,
2
months
UK
McBride[34] Depression
(CES-D
e)
EUC (115), Biomarker
Feedback (236)
12
months
USA
Coronary Heart
Disease (CHD)
Additional risk factor for CHD Christiansen
[35]
General Distress
(GHQ
c-12)
Not-screened (396),
Screened (904)
5 years Denmark
a State, Trait, Anxiety Inventory;
b Hospital Anxiety and Depression Scale;
c General Health Questionnaire;
d Nottingham Health Profile;
e Centre for
Epidemiologic Studies Depression Scale.
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Only one study assessed the impact of screening on
depression within four weeks of screening (n = 61) [33].
The SMD was -0.50 (95% CI -1.05, 0.06), indicating no
short term impact of screening on depression. Four stu-
dies [24,25,33,34] assessed depression four weeks or
longer after screening (n = 4,342). The pooled SMD was
0.04 (95% CI -0.12, 0.20), indicating no adverse effect of
screening upon depression beyond four weeks of
screening.
Two studies [25,33] provided sufficient data to enable
quantitative synthesis of short term depression by
screening test outcome (n = 3,204). The pooled estimate
of the overall standardised difference was 0.07 (95% CI
0.00, 0.14), providing marginal evidence for raised short
term depression in those screening positive. Two studies
[24,33] provided sufficient data to enable quantitative
synthesis of longer term depression by screening test
outcome (n = 1,273). The pooled estimate of the overall
standardised difference was 0.08 (95% CI -0.03, 0.19),
indicating no evidence of increased depression, one
month or more after screening.
Quality of Life
There were insufficient data to examine the impact of
screening on quality of life within four weeks of
screening.
Five studies [24,26,28,31,32] assessed mental quality of
life four weeks or longer after screening (n = 14,199).
The pooled SMD was 0.01 (95% CI -0.02, 0.04) indicat-
ing no adverse effect of screening upon mental quality
of life beyond four weeks of screening. Four studies
[25,26,28,30] examined the self-assessed health subscales
of quality of life four weeks or longer after screening (n
= 15,119). The pooled SMD was 0.00 (95% CI -0.04,
0.03) indicating no adverse effect of screening upon gen-
eral health beyond four weeks of screening. One study
reported quality of life using the Nottingham Health
Profile (n = 415) [29]. No adverse effect of screening
was found with standardised mean differences on scales
of energy -0.01 (-0.21, 0.18), emotional reactions 0.04
(-0.15, 0.23), pain -0.08 (-0.28, 0.11), physical mobility
0.02 (-0.17, 0.22) sleep 0.05 (-0.14, 0.24) or social isola-
tion 0.11 (-0.08, 0.31) respectively.
No data were available to examine quality of life in
line with test outcome at less than four weeks after
receipt of test results. Two studies [24,31] provided suf-
ficient data to enable quantitative synthesis of mental
q u a l i t yo fl i f eb ys c r e e n i n gt e s to u t c o m ei nt h el o n g e r
term (n = 1,379). The pooled estimate of the overall
standardised difference was 0.06 (95% CI -0.45, 0.57)
indicating little impact of test result on quality of life
(mental).
General Distress
No data were available to examine the impact of screen-
ing on general distress at less than four weeks after
receipt of test results. Only one study assessed general
distress in the longer term (n = 784) [35]. The SMD
was -0.03 (95% CI -0.15, 0.09), indicating no short term
impact of screening on general distress. One study
assessed suicide, a behavioural index of emotional dis-
tress [27], with no reported differences found between
study arms (OR 0.91 95% CI 0.61, 1.34).
Sensitivity analysis
Sensitivity analysis was conducted to explore the poten-
tial impact of screening approach (screening for disease
versus estimating disease risk) on the overall results.
Removal of studies estimating disease risk [33-35] had
no impact on the primary outcome. Sensitivity analysis
was also conducted to assess the impact of measure-
ments on the primary outcome measure as assessed in
both non-attenders and attenders versus attenders only.
Removal of studies assessing the both non-attenders and
attenders [26] had no impact on the primary outcome.
Sensitivity analysis was also conducted to investigate the
impact of disease type on overall results (i.e.t h o s e
Table 2 Analysis of emotional impact of screening
Measure Time Comparison k n Z p SMD 95%CI I
2
Anxiety < 4 weeks Screened vs. Not-Screened 1 61 1.76 0.08 -0.50 -1.06 to 0.06 -
> 4 weeks Screened vs. Not-Screened 5 5190 0.10 0.92 0.01 -0.10 to 0.11 58%
< 4 weeks Screen +ve vs. Screen -ve 2 2511 1.44 0.15 0.06 -0.02 to 0.14 0%
> 4 weeks Screen +ve vs. Screen -ve 2 1273 0.20 0.84 -0.05 -0.53 to 0.44 64%
Depression < 4 weeks Screened vs. Not-Screened 1 61 1.74 0.08 -0.50 -1.05 to 0.06 -
> 4 weeks Screened vs. Not-Screened 4 4342 0.46 0.65 0.04 -0.12 to 0.20 73%
< 4 weeks Screen +ve vs. Screen -ve 2 3204 1.86 0.06 0.07 0.00 to 0.14 0%
> 4 weeks Screen +ve vs. Screen -ve 2 1273 1.37 0.17 0.08 -0.03 to 0.19 0%
QoL Mental > 4 weeks Screened vs. Not-Screened 5 14,199 0.57 0.57 0.01 -0.02 to 0.04 88%
> 4 weeks Screen +ve vs. Screen -ve 2 1379 0.24 0.81 0.06 -0.45 to 0.57 0%
QoL Self-Assessed Health > 4 weeks Screened vs. Not-Screened 4 15,199 0.18 0.85 0.00 -0.04 to 0.03 0%
Note. CI = Confidence Interval; SMD = Standardised Mean Difference; I
2 = homogeneity test; k = number of studies contributing to meta-analyses.
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these studies had no impact on the primary outcome
with the exception of mental quality of life between
screen positive and screen negative groups.
Discussion
We found no evidence that undergoing screening has an
adverse emotional impact when assessed four or more
weeks after screening. Too few studies assessed
(a) Anxiety 
Study or Subgroup
Ashton 2002
Eborall 2007
Park 2008
Sanderson 2008
Torgerson 1997
Total (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 9.57, df = 4 (P = 0.05); I² = 58%
Test for overall effect: Z = 0.10 (P = 0.92)
Mean
30.19
33.3
37.3
6.76
37.3
SD
11.16
12
10.9
4.63
13.4
Total
1230
2210
64
43
581
4128
Mean
31.53
32.8
34.1
5.91
37.5
SD
12.14
11.8
12.1
4.1
12.9
Total
726
304
168
18
566
1782
Weight
31.3%
27.0%
10.5%
3.6%
27.6%
100.0%
IV, Random, 95% CI
-0.12 [-0.21, -0.02]
0.04 [-0.08, 0.16]
0.27 [-0.02, 0.56]
0.19 [-0.36, 0.74]
-0.02 [-0.13, 0.10]
0.01 [-0.10, 0.11]
Screened Not Screened Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours Screened Favours Not Screened
 
(b) Depression 
 
Study or Subgroup
Ashton 2002 (AAA)
Christensen 2004 (CHD)
Eborall 2007 (Diabetes)
McBride 2002 (L.cancer)
Sanderson 2008 (L.cancer)
Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 11.24, df = 3 (P = 0.01); I² = 73%
Test for overall effect: Z = 0.46 (P = 0.65)
Mean
3.15
23.01
4.22
10.07
3.54
SD
2.86
6.75
3.39
6.3
3.37
Total
1230
784
2833
236
43
4342
Mean
3.48
23.19
4.03
8.49
3.47
SD
3.15
6.9
3.35
6.43
3.89
Total
726
395
378
115
18
1237
Weight
36.0%
0.0%
34.5%
22.6%
7.0%
100.0%
IV, Random, 95% CI
-0.11 [-0.20, -0.02]
-0.03 [-0.15, 0.09]
0.06 [-0.05, 0.16]
0.25 [0.02, 0.47]
0.02 [-0.53, 0.57]
0.04 [-0.12, 0.20]
Screened Not Screened Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours Screened Favours Not Screened  
 
 
(c) Mental QoL 
 
Study or Subgroup
Torgerson 1997
Andersen 2007
Ashton 2002
Hansen 2008
Taylor 2004
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.04, df = 4 (P = 0.73); I² = 0%
Test for overall effect: Z = 0.57 (P = 0.57)
Mean
71.7
44.9
50.68
81.1
54.09
SD
18.3
5.9
9.36
17.7
7.59
Total
610
128
1230
4821
149
6938
Mean
71.4
44.8
50.03
81.1
54.4
SD
18.6
5.8
9.82
17.2
7.1
Total
605
139
726
5612
179
7261
Weight
8.7%
1.9%
13.0%
74.1%
2.3%
100.0%
IV, Random, 95% CI
0.02 [-0.10, 0.13]
0.02 [-0.22, 0.26]
0.07 [-0.02, 0.16]
0.00 [-0.04, 0.04]
-0.04 [-0.26, 0.18]
0.01 [-0.02, 0.04]
Screened Not-Screened Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours Not Screened Favours Screened  
 
 
 
(d) Self Assessed Health 
 
Study or Subgroup
Eborall 2007
Hansen 2008
Park 2008
Torgerson 1997
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.24, df = 3 (P = 0.74); I² = 0%
Test for overall effect: Z = 0.18 (P = 0.85)
Mean
3.16
73.5
2.92
69.7
SD
0.86
21.3
0.86
21.7
Total
2874
4821
64
600
8359
Mean
3.21
73.4
2.95
69.8
SD
0.81
21.1
0.87
20.8
Total
383
5612
168
597
6760
Weight
10.3%
79.1%
1.4%
9.1%
100.0%
IV, Random, 95% CI
-0.06 [-0.17, 0.05]
0.00 [-0.03, 0.04]
-0.03 [-0.32, 0.25]
-0.00 [-0.12, 0.11]
-0.00 [-0.04, 0.03]
Screened Not Screened Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-0.2 -0.1 0 0.1 0.2
Favours Not Screened Favours Screened
Figure 2 Forest plots depicting the impact after four weeks of screening.
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Page 7 of 10outcomes before four weeks to comment on the shorter
term emotional impact of screening. Subgroup compari-
sons between those receiving positive and those receiv-
ing negative test results reveal a small, transient impact
of being informed of an elevated risk of disease, discern-
ible on depression.
These findings are consistent with psychological the-
ories of self-regulation which describe the complex ways
in which humans maintain emotional equilibrium while
managing threats [42]. Managing threats in the current
context includes engaging in behaviours to reduce
threats to health, as well as using cognitive strategies to
minimise the severity or likelihood of the threat. Both of
these can reduce emotional distress. Emotional distress
is a common and adaptive initial response to risk notifi-
cation, but, as replicated in the current review, this has
usually dissipated by one month [3]. These findings also
reflect those from existing, but disparate and methodo-
logically less robust reviews, which have focused on
screening for inherited or genetic conditions
[14-16,43,44]. Only one previous review has assessed the
impact of screening for a broader range of conditions
[3].
The strength of our review is that it is the first sys-
tematic review with meta- analysis involving compari-
sons of emotional outcomes assessed in RCTs. The
findings are therefore more robust than those from
existing reviews. The findings of the review may, how-
ever, reflect some bias evident in the conduct of the
reviewed studies. This includes bias from sampling as
well as from the measures used. Only half of the studies
reported outcomes on 80% or more of participants.
Consequently, pooled comparisons often contain a small
number of studies. Examination of follow-up between
randomised arms, however, revealed similar levels of
attrition between screened and not-screened groups. Of
concern is that those lost to follow-up may have been
those who experienced higher levels of distress than
those who remained in the studies, for which there is
some evidence [12,45]. The studies also varied in the
populations sampled in the intervention arm. In some
trials, this included attenders and non-attenders [26,27]
and in others, only attenders [21,22,25-30,33,34]. The
measures used to assess emotional outcomes may have
been inappropriate or insufficiently sensitive to detect
adverse emotional outcomes. All the included studies
used standardised measures of generalised emotional
functioning. Such measures are not designed to detect
subtle changes, such as worry about health, that do not
affect general mood states. The claims that can be made
from the current review therefore concern general levels
of functioning and not more subtle impacts of screening
on worries specifically related to health.
The review was also limited by the relatively large
heterogeneity of the included studies, as reflected in
the I
2 scores (Figure 2), particularly those above 50%.
The studies varied greatly in the demographic charac-
teristics of participants, the diseases for which screen-
ing was being undertaken as well as the processes of
screening. Pooled comparisons combined studies
screening for disparate disease types which may have
impacted on the findings. Sensitivity analysis revealed
no differences in overall results by disease type with
the exception of mental quality of life between
screened versus non screened groups. Future reviews
might consider the impact of disease specific factors
such as prevalence and severity, and test specific fac-
tors such as sensitivity and specificity factors on emo-
tional responses. One of the studies included was
tailored specifically for smokers [33], a further two
involved multiple screening procedures [31,32], one of
which involved screening for the risk of several dis-
eases [31]. The studies are likely to have varied in the
information provided and support offered to partici-
pants, but insufficient detail was provided to allow
subgroup analysis on this in the current review. Exist-
ing evidence suggests this is likely to have affected
emotional responses, particularly in the short-term
[46-50].
Conclusion
The results of this review reduce uncertainty about
emotional outcomes and suggest that, provided other
criteria for screening are met [51], there are few if any
grounds for not screening on the basis that it has
adverse longer term emotional outcomes.
PubMed Search Strategy
("Genetic Screening"[Majr] OR “Mass Screening"[Majr]
OR “Risk Assessment"[Majr] OR ((cancer OR diabetes
OR heart OR cardiac OR cardioavasc* OR AIDS OR
HIV OR osteoporosis OR Huntington*) AND screen*))
AND (emotion* OR anxiety OR distress* OR depression
OR mood or anger or GHQ OR K10 OR (quality of
life)) NOT (fetal distress OR postpartum depression OR
prenatal OR newborn OR maternal) NOT decision aid*
[ti] NOT intervention*[ti] AND ((Randomized Con-
trolled Trial[ptyp]).
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